SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
0.8879
-0.0004 (-0.05%)
At close: Apr 2, 2026, 4:00 PM EDT
0.8800
-0.0079 (-0.89%)
After-hours: Apr 2, 2026, 7:59 PM EDT
SCYNEXIS Revenue
In the year 2025, SCYNEXIS had annual revenue of $20.60M with 449.95% growth. SCYNEXIS had revenue of $17.20M in the quarter ending December 31, 2025, with 1,660.70% growth.
Revenue (ttm)
$19.16M
Revenue Growth
+411.40%
P/S Ratio
1.93
Revenue / Employee
$1,144,500
Employees
18
Market Cap
39.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 20.60M | 16.86M | 449.95% |
| Dec 31, 2024 | 3.75M | -136.40M | -97.33% |
| Dec 31, 2023 | 140.14M | 135.05M | 2,652.72% |
| Dec 31, 2022 | 5.09M | -8.07M | -61.32% |
| Dec 31, 2021 | 13.16M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 121.00K | -136.00K | -52.92% |
| Dec 31, 2018 | 257.00K | - | - |
| Dec 31, 2017 | 257.00K | - | - |
| Dec 31, 2016 | 257.00K | - | - |
| Dec 31, 2015 | 257.00K | -999.00K | -79.54% |
| Dec 31, 2014 | 1.26M | -8.31M | -86.87% |
| Dec 31, 2013 | 9.57M | 156.00K | 1.66% |
| Dec 31, 2012 | 9.41M | -3.42M | -26.67% |
| Dec 31, 2011 | 12.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| InterCure | 72.16M |
| Rockwell Medical | 69.26M |
| Aytu BioPharma | 62.64M |
| Cumberland Pharmaceuticals | 44.52M |
| Zhengye Biotechnology Holding | 21.46M |
| TherapeuticsMD | 2.80M |
| BioXcel Therapeutics | 642.00K |
| Talphera | 28.00K |
SCYX News
- 2 days ago - Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million - Business Wire
- 2 days ago - SCYNEXIS Announces $40.0 Million Private Placement - GlobeNewsWire
- 2 days ago - SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - GlobeNewsWire
- 4 weeks ago - SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247 - GlobeNewsWire
- 6 weeks ago - CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors - GlobeNewsWire
- 3 months ago - SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - GlobeNewsWire
- 4 months ago - SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK - GlobeNewsWire